Aligos therapeutics reports recent business progress and third quarter 2024 financial results

South san francisco, calif., nov. 06, 2024 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2024.
ALGS Ratings Summary
ALGS Quant Ranking